Nothing good lasts forever and it looks like Gilead (GILD) has brought a little dose of reality back to the Hepatitis C market. While Hepatitis C plays like Pharmasset (acquired by Gilead), Idenix (IDIX), Achillion (ACHN), and Inhibitex (acquired by Bristol-Myers (BMY)) were white-hot throughout much of 2011 on investor enthusiasm for a new generation of drugs that hold promise for very nearly curing the disease, some disappointing data in a small study shows there's no perfect drug yet.
A Disappointing Result In A Tough Crowd
Gilead announced that a Phase II study of GS-7977 (the start drug acquired in the Pharmasset deal) and ribavirin failed to show efficacy in treating so-called non-responders (that is, HCV patients who have shown insufficient response to prior therapy). In fact, within 4 weeks of stopping treatment three-quarters of the patients (6 of 8) showed significant relapse and higher viral loads.
Please read more here:
Gilead's Electron Data Brings Some Reality Back To The Hep C Market
No comments:
Post a Comment